The histopathology exam revealed a primary well-differentiated (grade 1) endometrioid adenocarcinoma of the fallopian tube. This patient had a strong family history of breast and ovarian cancers ...
The dose-expansion phase will focus on evaluating NXP800 in patients selected using biomarker analysis, initially in clear cell ovarian and endometrioid ovarian cancers. Preclinical studies in cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback